Designed in 1948, the #NHS pay structure has not kept up with the changes in women’s position in society. The medical #genderpaygap in England has worsened as a result of #COVID19, and does not narrow until aged 65. Jane Dacre et al. Comment: hubs.li/H0CHQfJ0 Panel: Recommendations acro...
A recent review shows that the total medical #genderpaygap in England is 24·4% for hospital doctors, 33·5% for general practitioners, and 21·4% for clinical academics.
A severe reduction in child-care provision during the #COVID19 pandemic will have disproportionately stalled the careers of women in medicine; it is likely that most accommodations to adjust to the shortage of child-care will have been made by female doctors.
Furthermore, the effects of the COVID-19 pandemic are likely to be compounded for female ethnic minority doctors as pre-existing assumptions and stereotypes unduly affect female BAME professionals.

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with The Lancet

The Lancet Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @TheLancet

18 Dec
NEW—COVID-19 causes more severe disease than seasonal influenza, confirms a Study of French national data from over 130,000 hospitalised patients published today in @LancetRespirMed: hubs.li/H0CRd__0 (1/4) Image
Nearly twice as many people were admitted to hospital for COVID-19 at the height of the pandemic than were for influenza at the peak of the 2018/2019 flu season; (COVID-19, 89,530 patients vs influenza, 45,819 patients) (2/4)
The death rate among COVID-19 patients was almost three times higher (number of deaths: COVID-19 15,104/89,530 [16.9%] vs influenza 2640/45,819 [5.8%]), and a greater proportion of COVID-19 patients experienced severe illness requiring intensive care. (3/4) Image
Read 4 tweets
8 Dec
NEW—First full results from interim analysis confirm that the Oxford #COVID19 vaccine is safe and efficacious against symptomatic COVID-19 disease: hubs.li/H0CcSs60 (1/6)
The vaccine protects against symptomatic disease in 70% of cases – with vaccine efficacy of 62% for those given two full doses, and of 90% in those given a half then a full dose. (2/6) Table 2: Efficacy against SARS-CoV-2 more than 14 days after
The first clinical efficacy results of the vaccine are based on a pre-specified pooled analysis of phase 3 trials in UK and Brazil (11,636 people), alongside safety data from 23,745 participants in 4 trials in the UK, Brazil and South Africa. (3/6) Table 1: Baseline characteristics of participants in the pri
Read 6 tweets
28 Sep
NEW—Radiotherapy following prostate cancer surgery can safely be avoided for many men: finding from a prospectively planned systematic review & meta-analysis assessing results from 2153 men enrolled across 3 trials, with median follow-up of at least 5 yrs hubs.li/H0x3LxP0 Image
NEW—Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial hubs.li/H0x5PXH0 (Trial 1/3) Image
NEW—Adjuvant radiotherapy vs early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial @TheLancetOncol (Trial 2/3) hubs.li/H0x69kT0 ImageImage
Read 5 tweets
21 Sep
This week we're celebrating #PeerRevWeek20 with the theme #TrustInPeerReview

NEW Editorial discusses the enormous effect that #COVID19 has had on scientific publishing as well as the increased public interest in & scrutiny of research & science hubs.li/H0wwv5L0 Image
In recognition of #PeerRevWeek20 we would like to say thank you to our reviewers for their essential role in maintaining the advancement of science and medicine through helping us to identify the most robust and impactful work #TrustInPeerReview hubs.li/H0wB2cg0
From peer review, through our in-house editing process, production, to publication and beyond, the entire Lancet team brings a wealth of expertise in scholarly publishing

On #PeerRevWeek20, follow the journey of a paper at @TheLancet journals hubs.li/H0wB2nM0
Read 6 tweets
14 Sep
Non-communicable diseases & injuries (NCDI) cause more death & disability at every age among the world’s poorest billion than in wealthy countries— new @NCDIpoverty Commission provides cost-effective & equitable interventions to address #NCDIPoverty hubs.li/H0wd1XP0 Image
Among the world’s poorest people, almost 800,000 under age 40 die each year from #NCDs & injuries

The @NCDIpoverty Commission outlines how to reverse the neglect of the world’s most marginalised people living with these conditions #NCDIPoverty hubs.li/H0wd1XP0 Image
"Partnerships & coalition building will be key not only within the #NCD community but also in alliances forged with the UHC & anti-poverty movements"—The Lancet Editors reflect on the #NCDIPoverty Commission calling for expansion of the global NCD agenda hubs.li/H0wfQsN0 Image
Read 6 tweets
10 Sep
New research mapping global trends in vaccine confidence across 149 countries between 2015-19 & based on data from over 284,000 adults surveyed about their views on whether vaccines are important, safe and effective, reveals vaccine hesitancy hotspots hubs.li/H0w0gKb0
Findings from largest study of global vaccine confidence to date finds that although confidence remains low across Europe, there are signs that it is increasing for much of Europe, including France hubs.li/H0w0gKb0 Trends in the perceived saf...
Largest global vaccine confidence survey suggests that overall confidence in vaccines—including safety, effectiveness, and importance—fell in Indonesia 🇮🇩, the Philippines 🇵🇭, Pakistan 🇵🇰, and South Korea 🇰🇷 between Nov 2015 and Dec 2019 hubs.li/H0vXTbc0 Image
Read 7 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!